As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer cares to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this applicatin to become a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, research nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the cooperative group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to national cooperative group activities, including SWOG, RTOG, GOG, ACRIN, and ACOSOG, as well as to other NCI-related committees and initiatives. Expanding this effort to the NCTN concept will increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. Continuing a strong track record in cooperative group translational and clinical research leadership, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for cooperative group trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials hub for accrual to NCI-sponsored studies throughout North-Central California, expansion to the NCTN creates a number of additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will achieve the coals of the NCTN and ensure robust accrual.

Public Health Relevance

This UCDCCC UI0 program, to be pursued by an already well-established and accomplished multidisciplinary clinical research team, will provide scientific and administrative leadership to NCTN, while also ensuring robust accrual and access to cooperative group trials throughout the North-Central California community. This will contribute to the NCTN's goal for improving human health through the quality completion of large innovative, clinical trials across a wide range of tumor types.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180846-05
Application #
9439722
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-14
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Salahudeen, Ameen Abdulla; Patel, Manali I; Baas, Paul et al. (2017) Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer 18:5-12
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Tsao, Anne S; Moon, James; Wistuba, Ignacio I et al. (2017) Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol 12:1299-1308
Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91
Chow, Helen; Ghosh, Paramita M; deVere White, Ralph et al. (2016) A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer 122:1897-904
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5

Showing the most recent 10 out of 46 publications